3-phenylamino-indole | 80381-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-phenylamino-indole
• 英文别名: 3-Phenylaminoindole；N-phenyl-1H-indol-3-amine
• CAS: 80381-18-6
• 化学式: C₁₄H₁₂N₂
• 分子量: 208.263
• InChiKey: JTUAEJULYXDMIE-UHFFFAOYSA-N

物化性质

• 沸点：
  429.2±18.0 °C(Predicted)
• 密度：
  1.240±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-phenylamino-indole 在 1-Chloro-1H-indole-2,3-dione 作用下， 以 苯 为溶剂， 反应 2.0h， 以90%的产率得到3-phenylimino-indole
  参考文献：
  名称：

  Berti, Corrado; Greci, Lucedio, Synthetic Communications, 1981, vol. 11, # 9, p. 681 - 686

  摘要：

  DOI：
• 作为产物：
  描述：

  (2,3-二氢-1H-吲哚-3-基)-苯基-胺 在 盐酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.5h， 以72%的产率得到3-phenylamino-indole
  参考文献：
  名称：

  Banerji; Lai; Basak, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 2, p. 426 - 429

  摘要：

  DOI：

文献信息

• [EN] 1-HETEROCYCLYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES<br/>[FR] 1-HETEROCYCLYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES
  申请人：TIBOTEC PHARM LTD

  公开号：WO2005111047A1

  公开（公告）日：2005-11-24

  1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indo l-2-ones of formula (I): the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereo f, wherein n is 1, 2 or 3; R1 is hydrogen, cyano, halo, substituted carbonyl, methanimidamidyl, N-hydroxy- methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; X is NR2, O, S, SO, SO2; R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, which are optionally substituted; R2 is aryl subst ituted with -COOR4 ; or R2 is: (b-1); (b-2); -CpH2p-CH(OR14)-CqH2q-R15 (b-3); -CH2-CH2-(O-CH2 -CH2)m-OR14 (b-4); -CH2-CH2-(O-CH2-CH2)m-NR5aR5b (b-5); -a1=a2-a3=a4- is -CH=CH-CH=CH-; -N=CH-CH=CH-; -CH=N-CH=CH-; -CH=CH-N=CH-; -CH=CH-CH=N-; wherein hydrogen atoms in (c-1) - (c-5) may be replaced by certain radicals; R3 is a monocyclic or bicyclic aromatic heterocyclic ring system that can be substituted.

  公式（I）的1-杂环基-1,5-二氢吡啶并[3,2-b]吲哚-2-酮：其N-氧化物、盐、立体异构体形式、消旋混合物、前药、酯及其代谢物，其中n为1、2或3；R1为氢、氰基、卤素、取代的羰基、甲基亚胺基、N-羟基甲基亚胺基、单取代或双(C1-4烷基)甲基亚胺基、Het1或Het2；X为NR2、O、S、SO、SO2；R2为氢、C1-10烷基、C2-10烯基、C3-7环烷基，可选择性地取代；R2为芳基，取代基为-COOR4；或R2为：(b-1)；(b-2)；-CpH2p-CH(OR14)-CqH2q-R15（b-3）；-CH2-CH2-(O-CH2-CH2)m-OR14（b-4）；-CH2-CH2-(O-CH2-CH2)m-NR5aR5b（b-5）；-a1=a2-a3=a4-为-CH=CH-CH=CH-；-N=CH-CH=CH-；-CH=N-CH=CH-；-CH=CH-N=CH-；-CH=CH-CH=N-；其中（c-1）-（c-5）中的氢原子可被某些基团取代；R3为可取代的单环或双环芳香杂环环系统。
• [EN] 5-SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO'3,2-B! INDOL-2-ONES AND ANALOGS AS ANTI-VIRALS<br/>[FR] 1-PHENYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES 5-SUBSTITUTES ET ANALOGUES UTILISES EN TANT QU'ANTIVIRAUX
  申请人：TIBOTEC PHARM LTD

  公开号：WO2005111034A1

  公开（公告）日：2005-11-24

  Compounds of formula (I) the N-oxides, salts, stereoisomeric forms, prodrugs, esters and metabolites thereof, wherein X is NR2, O, S, SO, SO2; R1 is hydrogen, cyano, halo, a carbonyl derivative, methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)- methanimidamidyl, Het1 or Het2; n is 1, 2 or 3; R2 is (i) aryl substituted with a radical -COOR4; (ii) C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, substituted with aryl which is substituted with a radical -COOR4; (iii) C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, substituted with -NR5a-C(=NR5b)-NR5cR5d, -O-NR5a-C(=NR5b)-NR 5cR5d, -sulfonyl-R6, -NR7R8, -NR9R10, a radical (a-1), (a-2), (a-3), (a-4), (a-5); or (iv) a radical of formula: (a-6), (b-2), -CpH2p-CH(OR14)-CqH2q-R15; -CH2-CH2-(O-CH2-CH2)m-OR14; -CH2-CH2-(O- CH2-CH2)m-NR17aR 17b; R3 is nitro, cyano, amino, halo, hydroxy, C1-4alkyloxy, a carbonyl derivative, methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het1.

  式(I)的化合物，其N-氧化物，盐，立体异构体形式，前药，酯及其代谢物，其中X为NR2，O，S，SO，SO2；R1为氢，氰基，卤素，羰基衍生物，甲基亚胺基，N-羟基甲基亚胺基，单或双(C1-4烷基)-甲基亚胺基，Het1或Het2；n为1，2或3；R2为(i)芳基，其上取代有一个基团-COOR4；(ii)C1-10烷基，C2-10烯基，C3-7环烷基，上面取代有芳基，芳基上取代有一个基团-COOR4；(iii)C1-10烷基，C2-10烯基，C3-7环烷基，上面取代有-NR5a-C(=NR5b)-NR5cR5d，-O-NR5a-C(=NR5b)-NR5cR5d，-磺酰基-R6，-NR7R8，-NR9R10，一个基团(a-1)，(a-2)，(a-3)，(a-4)，(a-5)；或(iv)式的基团：(a-6)，(b-2)，-CpH2p-CH(OR14)-CqH2q-R15；-CH2-CH2-(O-CH2-CH2)m-OR14；-CH2-CH2-(O-CH2-CH2)m-NR17aR17b；R3为硝基，氰基，氨基，卤素，羟基，C1-4烷氧基，羰基衍生物，甲基亚胺基，单或双(C1-4烷基)甲基亚胺基，N-羟基甲基亚胺基或Het1。
• [EN] 4-SUBSTITUTED-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES<br/>[FR] 1,5-DIHYDROPYRIDO[3,2-B]INDOL-2-ONES SUBSTITUEES EN POSITION 4
  申请人：TIBOTEC PHARM LTD

  公开号：WO2005111044A1

  公开（公告）日：2005-11-24

  4-substituted 1,5-dihydro-pyrido[3,2-b]indol-2-ones of formula (I): the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein n is 1, 2 or 3; R1 is hydrogen, cyano, halo, substituted carbonyl, methanimidamidyl, N-hydroxymethanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; X is NR 2, O, S, SO, SO2; R2 is hydrogen, C 1-10alkyl, C2-10alkenyl, C 3-7cycloalkyl, which are optionally substituted; R2 is aryl substituted with -COOR4 ; or R2 is: (b-1); (b-2); -CpH2p-CH(OR14 )-CqH 2q-R15(b-3); -CH2-CH2-(O-CH2-CH2)m-OR14 (b-4); -CH2-CH2-(O-CH2-CH2)m-NR5aR5b(b-5); -a1=a2-a3=a4- is -CH=CH-CH=CH-; -N=CH-CH=CH-; -CH=N-CH=CH-; -CH=CH-N=CH-; -CH=CH-CH=N-; wherein hydrogen atoms in (c-1) - (c-5) may be replaced by certain radicals; R3 is obtionally substituted phenyl or a monocyclic or bicyclic aromatic heterocyclic ring system that can be substituted; R21 is halo, hydroxy, amino, carboxyl, C1-6alkyl, C3-7cycloalkyl, arylC1-6alkyl, formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylo xy, -C(=O)-NR13R14; C1-6alkyloxy, arylC1-6alkyloxy, polyhaloC1-6alkyloxy, amino, mono or di(C1-6alkyl)amino, formylamino, C1-6alkylcarbonylamino, C1-6alkylsulfo nylamino, mercapto, C1-6alkylthio, arylthio, aryloxy, arylC1-6alkylthio, C1-6alkylsulfynyl, C1-6alkylsulfo nyl, aryl, arylamino, Het1, Het2.

  公式（I）的4-取代1,5-二氢吡啶并[3,2-b]吲哚-2-酮：其N-氧化物，盐，立体异构体形式，消旋混合物，前药，酯和代谢物，其中n为1、2或3；R1为氢，氰基，卤素，取代羰基，甲基亚胺基，N-羟甲基亚胺基，单或双(C1-4烷基)甲基亚胺基，Het1或Het2；X为NR 2，O，S，SO，SO2；R2为氢，C1-10烷基，C2-10烯基，C3-7环烷基，可选择地取代；R2为取代为-COOR4的芳基；或R2为：(b-1)；(b-2)；-CpH2p-CH(OR14)-CqH2q-R15(b-3)；-CH2-CH2-(O-CH2-CH2)m-OR14(b-4)；-CH2-CH2-(O-CH2-CH2)m-NR5aR5b(b-5)；-a1=a2-a3=a4-为-CH=CH-CH=CH-；-N=CH-CH=CH-；-CH=N-CH=CH-；-CH=CH-N=CH-；-CH=CH-CH=N-；其中(c-1)-(c-5)中的氢原子可被某些基团取代；R3为可选择地取代的苯基或可以被取代的单环或双环芳香杂环系统；R21为卤素，羟基，氨基，羧基，C1-6烷基，C3-7环烷基，芳基C1-6烷基，甲酰基，C1-6烷基羰基，C1-6烷氧羰基，C1-6烷基羰氧基，-C(=O)-NR13R14；C1-6烷氧基，芳基C1-6烷氧基，多卤C1-6烷氧基，氨基，单或双(C1-6烷基)氨基，甲酰氨基，C1-6烷基羰胺基，C1-6烷基磺酰氨基，巯基，C1-6烷基硫基，芳基硫基，芳氧基，芳基C1-6烷基硫基，C1-6烷基烯基基，C1-6烷基磺基，芳基，芳胺基，Het1，Het2。
• 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals
  申请人：Kesteleyn Rudolf Romanie Bart

  公开号：US20070238727A1

  公开（公告）日：2007-10-11

  Compounds of formula (I) the N-oxides, salts, stereoisomeric forms, prodrugs, esters and metabolites thereof, wherein X is NR 2 , O, S, SO, SO 2 ; R 1 is hydrogen, cyano, halo, a carbonyl derivative, methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C 1-4 alkyl)-methanimidamidyl, Het 1 or Het 2 ; n is 1, 2 or 3; R 2 is (i) aryl substituted with a radical —COOR 4 ; (ii) C 1-10 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, substituted with aryl which is substituted with a radical —COOR 4 ; (iii) C 1-10 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, substituted with —NR 5a —C(═NR 5b )—NR 5c R 5d , —O—NR 5a —C(═NR 5b )—NR 5c R 5d , -sulfonyl-R 6 , —NR 7 R 8 , —NR 9 R 10 , a radical (a-1), (a-2), (a-3), (a-4), (a-5); or (iv) a radical of formula: (a-6), (b-2), —C p H 2p —CH(OR 14 )—C q H 2q —R 15 ; —CH 2 —CH 2 —(O—CH 2 —CH 2 ) m —OR 14 ; —CH 2 —CH 2 —(O—CH 2 —CH2) m —NR 17a R 17b ; R 3 is nitro, cyano, amino, halo, hydroxy, C 1-4 alkyloxy, a carbonyl derivative, methanimidamidyl, mono- or di(C 1-4 alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het 1 .

  化合物的公式（I），包括其N-氧化物、盐、立体异构体形式、前药、酯和代谢物，其中X是NR2、O、S、SO、SO2；R1是氢、氰、卤素、一个羰基衍生物、甲酰亚胺基、N-羟甲酰亚胺基、单个或双个（C1-4烷基）-甲酰亚胺基、Het1或Het2；n为1、2或3；R2是（i）芳基，其被基团—COOR4取代；（ii）C1-10烷基、C2-10烯基、C3-7环烷基，被芳基取代，该芳基被基团—COOR4取代；（iii）C1-10烷基、C2-10烯基、C3-7环烷基，被—NR5a—C（═NR5b）—NR5cR5d、—O—NR5a—C（═NR5b）—NR5cR5d、-磺酰基-R6、—NR7R8、—NR9R10、一个基团（a-1）、（a-2）、（a-3）、（a-4）、（a-5）取代；或（iv）公式的基团：（a-6）、（b-2）、—CpH2p—CH（OR14）—CqH2q—R15；—CH2—CH2—（O—CH2—CH2）m—OR14；—CH2—CH2—（O—CH2—CH2）m—NR17aR17b；R3是硝基、氰基、氨基、卤素、羟基、C1-4烷氧基、一个羰基衍生物、甲酰亚胺基、单个或双个（C1-4烷基）甲酰亚胺基、N-羟甲酰亚胺基或Het1。
• 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones
  申请人：Kesteleyn Rudolf Romanie Bart

  公开号：US20070249655A1

  公开（公告）日：2007-10-25

  The present invention concerns combinations comprising a compound of formula (I) the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters or metabolites thereof, wherein n is 1, 2 or 3; R 1 is H, CN, halo, aminoC(═O), C(═O)OH, C 1-4 alkyloxyC(═O), C 1-4 alkylC(═O), mono- or di(C 1-4 alkyl)aminoC(═O), arylaminoC(═O), N-(aryl)-N-(C 1-4 alkyl)aminoC(═O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C 1-4 alkyl)methanimidamidyl, Het 1 or Het 2 ; R 2 is H, C 1-4 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, wherein said C 1-10 alkyl, C 2-10 alkenyl and C 3-7 cycloalkyl may be optionally substituted; R 3 is nitro, cyano, amino, halo, hydroxy, C 1-4 alkyloxy, hydroxyC(═O), aminoC(═O), C 1-4 alkyloxyC(═O), mono- or di(C 1-4 alkyl)aminoC(═O), C 1-4 alkylC(═O), methanimidamidyl, mono- or di(C 1-4 alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het 1 ; and another HIV inhibitor. The invention also concerns products comprising a compound of formula (I) and another HIV inhibitor, as a combined preparation for simultaneous, separate or sequential use in treatment of retroviral infections such as HIV infection, in particular, in the treatment of infections with multi-drug resistant retroviruses.

  本发明涉及一种组合物，包括式（I）化合物的N-氧化物、盐、立体异构体形式、混合物、前药、酯或其代谢物，其中n为1、2或3；R1为H、CN、卤素、氨基C（═O）、C（═O）OH、C1-4烷氧基C（═O）、C1-4烷基C（═O）、单烷基或二烷基氨基C（═O）、芳基氨基C（═O）、N-(芳基)-N-(C1-4烷基)氨基C（═O）、甲基亚胺基、N-羟基甲基亚胺基、单烷基或二烷基甲基亚胺基、Het1或Het2；R2为H、C1-4烷基、C2-10烯基、C3-7环烷基，其中所述的C1-10烷基、C2-10烯基和C3-7环烷基可以选择性地被取代；R3为硝基、氰基、氨基、卤素、羟基、C1-4烷氧基、羟基C（═O）、氨基C（═O）、C1-4烷氧基C（═O）、单烷基或二烷基氨基C（═O）、C1-4烷基C（═O）、甲基亚胺基、单烷基或二烷基甲基亚胺基、N-羟基甲基亚胺基或Het1；以及另一种HIV抑制剂。本发明还涉及包含式（I）化合物和另一种HIV抑制剂的产品，作为联合制剂，用于同时、分离或顺序治疗逆转录病毒感染，例如HIV感染，特别是治疗多药耐药逆转录病毒感染。